

Inventor(s): Anderson, et al.

Appln. No.: 09 383,916

Series Code ↑

Serial No. ↑

Filed: August 26, 1999

Hon. Commissioner of Patents
Washington, D.C. 20231

Group Art Unit 1644

Examiner: P. Gambel

Atty. Dkt. P 0275716 1995-30-0233D1

M#

Client Ref

Appln. Title: HUMAN B7.1 PRIMATIZED
ANTIBODIES AND TRANSFECTOMAS
EXPRESSING SAID ANTIBODIES

Sir:

REPLY/AMENDMENT/LETTER

Date: January 22, 2003

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated herinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim A. <input type="checkbox"/> NOT made B. <input type="checkbox"/> Withdrawn C. <input type="checkbox"/> made herewith D. <input type="checkbox"/> made previously For B & C See Required Separate Paper (Pat-256)		Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims		**minus	0	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims		***minus	0	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)					add	+ \$280/\$140 =	+ \$0 104/204
5. Original due Date: January 22, 2003		<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo)	\$110/\$55 =				115/215
		(2 mos)	\$410/\$205 =		+ \$0		116/216
		(3 mos)	\$930/\$465 =				117/217
		(4 mos)	\$1,450/\$725 =				118/218
		(5 mos)	\$1,970/\$985 =				128/228
7. Enter any previous extension fee paid since above original due date and subtract					- \$0		
8.					Extension Fee	+ \$0	
9. If Terminal Disclaimer attached, add Rule 20(d) official fee					+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c),					+ \$180	+ \$0	126
or if Rule 97(d) Request					+ \$180	+ \$0	126
11. After-Final Request Fee per rules 129(a) and 17(r)					+ \$750/370	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b).....					x \$750/375 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)					+ \$750/375	+ \$0	1179/1279
14. Petition fee for						+ \$0	
15.					TOTAL FEE =	\$	
16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".					PLEASE CHARGE OUR DEP. ACCT		
17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.							
18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.							

Our Deposit Account No. 03-3975)

(Our Order No. 037003 0275716

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Robin L. Teskin

Reg. No. 35,030


P.O. Box 10500
McLean, VA 22102
Tel: (703) 905-2000

Sig:

Fax: (703) 905-2500
Tel: (703) 905-2200

Atty/Sec: RLT/DJM

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments



#22/E
1/30/03
gnd

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Darrell R. Anderson et al.

Group Art Unit: 1644

Application Serial No. 09/383,916

Examiner: Phillip Gambel

Filed: August 26, 1999

Title: HUMAN B7.1-SPECIFIC PRIMATIZED ANTIBODIES AND TRANSFECTOMAS
EXPRESSING SAID ANTIBODIES

* * * * *

REPLY PURSUANT TO 37 C.F.R. §1.111

RECEIVED

JAN 24 2003

TECH CENTER 1600/2900

Hon. Commissioner of Patents

Washington, D.C. 20231

Sir:

In response to the Office Action [Non-Final Rejection] dated October 22, 2002, please amend the above-identified application as follows.

In the Claims:

Please cancel claims 41-42 and 44-49. ✓ ✓ ✓ ✓

Please amend the claims as follows:

E1 1 ~~43~~. (Amended) A method of treatment that comprises blocking the B7.1/CD28 interaction in a subject having psoriasis, by administering an anti-B7.1 antibody selected from the group consisting of antibodies having the same epitopic specificity as (i) an antibody having as its variable light sequence and variable heavy sequence the amino acid sequence of SEQ ID NO:2 and SEQ ID NO:4 respectively; (ii) an antibody having as its variable light sequence and variable heavy sequence the amino acid sequence of SEQ ID NO:6 and SEQ ID NO:8 respectively; and (iii) an antibody having as its variable light sequence and variable heavy sequence the amino acid sequence of SEQ ID NO:10 and SEQ ID NO:12 respectively, whereby a subject having psoriasis is treated.

E2 5 ~~53~~. (Amended) The method of Claim ~~43~~ which comprises administration of an antibody having as its variable light and heavy chain sequences the amino acid sequence contained in SEQ ID NOs:2 and 4 respectively.

87

g